MY160392A - Triptolide prodrugs - Google Patents
Triptolide prodrugsInfo
- Publication number
- MY160392A MY160392A MYPI2011005335A MYPI2011005335A MY160392A MY 160392 A MY160392 A MY 160392A MY PI2011005335 A MYPI2011005335 A MY PI2011005335A MY PI2011005335 A MYPI2011005335 A MY PI2011005335A MY 160392 A MY160392 A MY 160392A
- Authority
- MY
- Malaysia
- Prior art keywords
- formula
- compounds
- triptolide prodrugs
- triptolide
- prodrugs
- Prior art date
Links
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17624909P | 2009-05-07 | 2009-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY160392A true MY160392A (en) | 2017-03-15 |
Family
ID=42244313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2011005335A MY160392A (en) | 2009-05-07 | 2010-05-07 | Triptolide prodrugs |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8507552B2 (OSRAM) |
| EP (1) | EP2427467B1 (OSRAM) |
| JP (3) | JP6000122B2 (OSRAM) |
| KR (1) | KR101821823B1 (OSRAM) |
| CN (1) | CN102596977B (OSRAM) |
| AU (1) | AU2010245669B2 (OSRAM) |
| BR (1) | BRPI1014802B8 (OSRAM) |
| CA (2) | CA2964631A1 (OSRAM) |
| DK (1) | DK2427467T3 (OSRAM) |
| EA (1) | EA021135B1 (OSRAM) |
| ES (1) | ES2552163T3 (OSRAM) |
| MX (1) | MX2011011776A (OSRAM) |
| MY (1) | MY160392A (OSRAM) |
| PL (1) | PL2427467T3 (OSRAM) |
| PT (1) | PT2427467E (OSRAM) |
| SG (1) | SG175885A1 (OSRAM) |
| WO (1) | WO2010129918A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9150600B2 (en) | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
| KR20150059746A (ko) | 2012-08-23 | 2015-06-02 | 세네스텍 인코포레이티드 | 포유동물의 번식 능력을 감소시키는 방법 |
| WO2014047783A1 (zh) * | 2012-09-25 | 2014-04-03 | 鼎泓国际投资（香港）有限公司 | 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用 |
| WO2014167581A2 (en) * | 2013-04-01 | 2014-10-16 | Laurus Labs Private Limited | An improved process for the preparation of triptolide prodrugs |
| SG11201802915WA (en) * | 2015-09-11 | 2018-05-30 | Ys Ac Co Ltd | Cancer treatment composition combining anti-cd26 antibody and other anticancer agent |
| CN109942665B (zh) * | 2018-04-02 | 2021-04-06 | 欣凯医药化工中间体（上海）有限公司 | 雷公藤内酯醇衍生物及其制备方法和应用 |
| CN110551171B (zh) * | 2018-05-31 | 2021-07-27 | 欣凯医药化工中间体（上海）有限公司 | 一种雷公藤内酯醇衍生物的制备方法 |
| WO2020056174A1 (en) | 2018-09-13 | 2020-03-19 | Minneamrita Therapeutics, LLC | Triptolide and prodrugs thereof for use in methods to treat fibrosis, nash, and nafld |
| WO2021221179A1 (ja) * | 2020-04-28 | 2021-11-04 | 国立大学法人高知大学 | ヒト膵癌オルガノイドを用いたマウスモデルの樹立 |
| JP2023538424A (ja) | 2020-08-21 | 2023-09-07 | ルヤン コーポレイション | トリプトリドコンジュゲートおよびその使用 |
| CN115227829B (zh) * | 2022-02-22 | 2023-10-13 | 成都中医药大学 | 酸敏感性适配体雷公藤甲素偶联物及应用 |
| WO2024186320A1 (en) | 2023-03-09 | 2024-09-12 | Minneamrita Therapeutics Llc | Drug combination for treatment of pancreatic cancer |
| WO2024187139A1 (en) | 2023-03-09 | 2024-09-12 | Minneamrita Therapeutics Llc | Drug combination for treatment of gastric cancer |
| JP7759145B2 (ja) | 2023-03-09 | 2025-10-23 | ミネアムリタ セラピューティクス， エルエルシー | 胃癌の治療のための薬物の組み合わせ |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| US5759550A (en) | 1993-05-06 | 1998-06-02 | Pharmagenesis, Inc. | Method for suppressing xenograft rejection |
| US5609991A (en) | 1995-02-10 | 1997-03-11 | Morton International, Inc. | Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging |
| US5663335A (en) | 1996-03-01 | 1997-09-02 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
| US5962516A (en) | 1997-02-28 | 1999-10-05 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
| US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| US6548537B1 (en) | 1998-09-02 | 2003-04-15 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
| AU764123B2 (en) | 1998-09-02 | 2003-08-07 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
| AU3365800A (en) | 1999-02-16 | 2000-09-04 | Board Of Trustees Of The Leland Stanford Junior University | Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells |
| AU5368699A (en) | 1999-04-16 | 2000-11-02 | Chengdu Diao Pharmaceutical Group Company Limited | Derivatives of triptolide, and preparation and uses thereof |
| US6294546B1 (en) | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6620843B2 (en) * | 2001-01-19 | 2003-09-16 | Pharmagenesis | Anticancer treatment using triptolide prodrugs |
| EP1390358A4 (en) * | 2001-03-15 | 2004-06-16 | Pharmagenesis Inc | AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNOMODULATORS AND ANTICROPHES |
| KR20100101011A (ko) * | 2001-12-21 | 2010-09-15 | 에이자이 아이엔씨. | 알콜 및 페놀의 수용성 포스포노옥시메틸 유도체를 제조하는 방법 |
| CA2485794C (en) * | 2002-05-31 | 2012-10-16 | Pharmagenesis, Inc. | Triptolide derivatives for modulation of apoptosis and immunosuppression |
| CN100398544C (zh) * | 2002-09-18 | 2008-07-02 | 成都达远药物有限公司 | 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用 |
| WO2004058246A1 (en) | 2002-12-17 | 2004-07-15 | Pharmagenesis, Inc. | Triptolide derivatives as immunomodulator and anticancer agents |
| CN1223595C (zh) | 2002-12-27 | 2005-10-19 | 中国科学院上海药物研究所 | 雷公藤内酯醇衍生物及其应用 |
| US6943259B2 (en) | 2003-02-25 | 2005-09-13 | Pharmagenesis, Inc. | Halogenated triptolide derivatives as immunomodulators and anticancer agents |
| WO2005020887A2 (en) | 2003-06-27 | 2005-03-10 | Pharmagenesis, Inc. | Method for treatment of severe acute respiratory syndrome |
| WO2005062913A2 (en) | 2003-12-24 | 2005-07-14 | Pharmagenesis, Inc. | Triplide 5,6-derivatives as immunomodulators and anticancer agents |
| JP5252765B2 (ja) | 2003-12-26 | 2013-07-31 | 学校法人東京薬科大学 | 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤 |
| AU2005218610B2 (en) | 2004-03-02 | 2011-08-18 | Pharmagenesis, Inc. | Triptolide lactone ring derivatives as immunomodulators and anticancer agents |
| US20070244080A1 (en) | 2004-06-25 | 2007-10-18 | Pharmagenesis, Inc. | Method for Treatment of Inflammatory Disorders Using Triptolide Compounds |
| WO2007025031A2 (en) * | 2005-08-24 | 2007-03-01 | Cephalon, Inc. | Prodrugs of indanone and tetralone compounds |
| CN101049300A (zh) | 2006-04-04 | 2007-10-10 | 中国科学院上海药物研究所 | 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用 |
| EP2079699A1 (en) | 2006-07-25 | 2009-07-22 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
| JP5221514B2 (ja) * | 2007-03-06 | 2013-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物及びその製造方法 |
| FI20070574A0 (fi) * | 2007-07-30 | 2007-07-30 | Kuopion Yliopisto | Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke |
| WO2009023201A1 (en) | 2007-08-16 | 2009-02-19 | Myelorx Llc | Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents |
-
2010
- 2010-05-07 PL PL10719188T patent/PL2427467T3/pl unknown
- 2010-05-07 AU AU2010245669A patent/AU2010245669B2/en active Active
- 2010-05-07 MX MX2011011776A patent/MX2011011776A/es active IP Right Grant
- 2010-05-07 MY MYPI2011005335A patent/MY160392A/en unknown
- 2010-05-07 CN CN201080031839.1A patent/CN102596977B/zh active Active
- 2010-05-07 ES ES10719188.4T patent/ES2552163T3/es active Active
- 2010-05-07 PT PT107191884T patent/PT2427467E/pt unknown
- 2010-05-07 US US13/319,316 patent/US8507552B2/en active Active
- 2010-05-07 EA EA201190293A patent/EA021135B1/ru unknown
- 2010-05-07 DK DK10719188.4T patent/DK2427467T3/en active
- 2010-05-07 JP JP2012510027A patent/JP6000122B2/ja active Active
- 2010-05-07 KR KR1020117029123A patent/KR101821823B1/ko active Active
- 2010-05-07 CA CA2964631A patent/CA2964631A1/en not_active Abandoned
- 2010-05-07 CA CA2760953A patent/CA2760953C/en active Active
- 2010-05-07 BR BRPI1014802A patent/BRPI1014802B8/pt active IP Right Grant
- 2010-05-07 WO PCT/US2010/034117 patent/WO2010129918A1/en not_active Ceased
- 2010-05-07 EP EP10719188.4A patent/EP2427467B1/en active Active
- 2010-05-07 SG SG2011081122A patent/SG175885A1/en unknown
-
2014
- 2014-07-03 JP JP2014137661A patent/JP2014185181A/ja not_active Withdrawn
-
2016
- 2016-01-08 JP JP2016002236A patent/JP2016065099A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG175885A1 (en) | 2011-12-29 |
| CN102596977A (zh) | 2012-07-18 |
| EP2427467A1 (en) | 2012-03-14 |
| KR101821823B1 (ko) | 2018-01-24 |
| BRPI1014802B8 (pt) | 2021-05-25 |
| HK1168107A1 (en) | 2012-12-21 |
| US8507552B2 (en) | 2013-08-13 |
| BRPI1014802B1 (pt) | 2020-09-24 |
| EP2427467B1 (en) | 2015-08-05 |
| DK2427467T3 (en) | 2015-11-09 |
| JP6000122B2 (ja) | 2016-09-28 |
| MX2011011776A (es) | 2012-08-03 |
| US20120238529A1 (en) | 2012-09-20 |
| CA2760953C (en) | 2017-05-30 |
| EA021135B1 (ru) | 2015-04-30 |
| WO2010129918A8 (en) | 2011-01-20 |
| PT2427467E (pt) | 2015-11-19 |
| CA2964631A1 (en) | 2010-11-11 |
| EA201190293A1 (ru) | 2012-11-30 |
| KR20120015339A (ko) | 2012-02-21 |
| AU2010245669A1 (en) | 2011-12-01 |
| BRPI1014802A2 (pt) | 2016-04-05 |
| WO2010129918A1 (en) | 2010-11-11 |
| CA2760953A1 (en) | 2010-11-11 |
| JP2014185181A (ja) | 2014-10-02 |
| JP2012526148A (ja) | 2012-10-25 |
| ES2552163T3 (es) | 2015-11-26 |
| PL2427467T3 (pl) | 2016-04-29 |
| CN102596977B (zh) | 2016-06-29 |
| AU2010245669B2 (en) | 2015-11-26 |
| JP2016065099A (ja) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY160392A (en) | Triptolide prodrugs | |
| MY148253A (en) | Azaadamantane derivatives and methods of use | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
| EA201170872A1 (ru) | Ингибиторы протеинкиназы | |
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| MY172924A (en) | Neprilysin inhibitors | |
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| MY187718A (en) | Pharmaceutical formulations | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
| TN2011000291A1 (en) | Purine compounds | |
| MX2010009646A (es) | Agentes terapeuticos antivirales. | |
| MY153958A (en) | Lxr modulators | |
| MX2013002851A (es) | Inhibidores de tonum pectinacetilesterasa y metodos de su uso. | |
| WO2013109972A3 (en) | Therapeutic compounds | |
| PH12014502492A1 (en) | Pyrazole compounds as sglt1 inhibitors | |
| IN2012DN05081A (OSRAM) | ||
| TN2019000038A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| IN2012DN02000A (OSRAM) | ||
| PH12013500051A1 (en) | Crystalline form of a 3-phenoxymethylpyrrolidine compound | |
| MX2010003056A (es) | Polimorfos de valomaciclovir. | |
| GB2511240A (en) | Nitrofurfuryl substituted phenyl linked piperidino-oxadiazoline conjugates as anti-tubercular agents and process for the preparation thereof | |
| MX2013002656A (es) | Nuevo proceso. | |
| IN2012DN00346A (OSRAM) |